Skip to main content
SpringerLink
Log in

Update on Management of Squamous Cell Esophageal Cancer

  • Gastrointestinal Cancers (J Meyer, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

Esophageal cancer is the sixth most common cause of cancer death globally. Squamous cell carcinoma of the esophagus (ESCC) is the predominant histologic type in the world. Treatment strategies have evolved in the last decade and new paradigms are replacing traditional approaches at all stages of cancer. This review will summarize the epidemiology, diagnosis, staging, and treatment of esophageal squamous cell carcinoma.

Recent Findings

Novel approaches to screening may be cost-effective in regions with a high incidence of ESCC. Multi-disciplinary evaluation and treatment has become the standard of care. Endoscopic resection may be an option for early stage ESCC. Minimally invasive esophagectomy can be performed safely as a primary therapy or after-induction chemoradiation. Several recent studies have found a survival benefit to immunotherapy for patients with metastatic or persistent disease.

Summary

Multi-disciplinary evaluation and multi-modal therapy including cytotoxic chemotherapy, radiation, surgery, and immunotherapy have improved survival compared to surgery alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    Article  PubMed  Google Scholar 

  3. •Businello G, Parente P, Mastracci L, et al. The pathologic and molecular landscape of esophageal squamous cell carcinogenesis. Cancers (Basel). 2020;12(8). https://doi.org/10.3390/cancers12082160. A recent review of the molecular derrangements in squamous cell carcinoma of the esophagus.

  4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.

    CAS  PubMed  Google Scholar 

  5. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 2001;30(6):1415–25.

    CAS  PubMed  Google Scholar 

  6. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg. 2003;76(4):S1367-1369.

    PubMed  Google Scholar 

  7. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.

    PubMed  Google Scholar 

  8. Zhang H-Z, Jin G-F, Shen H-B. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 2012;31(6):281–6.

    PubMed  PubMed Central  Google Scholar 

  9. Toh Y, Oki E, Ohgaki K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15(2):135–44.

    CAS  PubMed  Google Scholar 

  10. Tanaka F, Yamamoto K, Suzuki S, et al. Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut. 2010;59(11):1457–64.

    CAS  PubMed  Google Scholar 

  11. Tai S-Y, Wu IC, Wu D-C, et al. Cigarette smoking and alcohol drinking and esophageal cancer risk in Taiwanese women. World J Gastroenterol. 2010;16(12):1518–21.

    PubMed  PubMed Central  Google Scholar 

  12. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59(1):39–48.

    CAS  PubMed  Google Scholar 

  13. Morita M, Kumashiro R, Kubo N, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol. 2010;15(2):126–34.

    PubMed  Google Scholar 

  14. Pandeya N, Webb PM, Sadeghi S, Green AC, Whiteman DC, Australian CS. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut. 2010;59(1):31–8.

    CAS  PubMed  Google Scholar 

  15. Cossentino MJ, Wong RK. Barrett’s esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14(3):128–35.

    PubMed  Google Scholar 

  16. Bakr O, Zhao W, Corley D. Gastroesophageal reflux frequency, severity, age of onset, family history and acid suppressive therapy predict Barrett esophagus in a large population. J Clin Gastroenterol. 2018;52(10):873–9.

    PubMed  PubMed Central  Google Scholar 

  17. Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett’s esophagus. Gastrointest Endosc. 2019;90(5):707-717.e701.

    PubMed  Google Scholar 

  18. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90(2):150–5.

    CAS  PubMed  Google Scholar 

  19. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130(11):883–90.

    CAS  PubMed  Google Scholar 

  20. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872–8.

    PubMed  Google Scholar 

  21. Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609–17.

    CAS  PubMed  Google Scholar 

  22. Wu MT, Lee YC, Chen CJ, et al. Risk of betel chewing for oesophageal cancer in Taiwan. Br J Cancer. 2001;85(5):658–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Wen CP, Tsai MK, Chung WS, et al. Cancer risks from betel quid chewing beyond oral cancer: a multiple-site carcinogen when acting with smoking. Cancer Causes Control. 2010;21(9):1427–35.

    PubMed  Google Scholar 

  24. Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in South Asians: a multicentre case-control study. Eur J Cancer. 2012;48(5):655–61.

    PubMed  Google Scholar 

  25. Goan YG, Chang HC, Hsu HK, Chou YP, Cheng JT. Risk of p53 gene mutation in esophageal squamous cell carcinoma and habit of betel quid chewing in Taiwanese. Cancer Sci. 2005;96(11):758–65.

    CAS  PubMed  Google Scholar 

  26. Lee CH, Lee JM, Wu DC, et al. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer. 2005;113(3):475–82.

    CAS  PubMed  Google Scholar 

  27. Lin S, Xu G, Chen Z, et al. Tea drinking and the risk of esophageal cancer: focus on tea type and drinking temperature. Eur J Cancer Prev. 2020;29(5):382–7.

    CAS  PubMed  Google Scholar 

  28. Yang X, Ni Y, Yuan Z, et al. Very hot tea drinking increases esophageal squamous cell carcinoma risk in a high-risk area of China: a population-based case-control study. Clin Epidemiol. 2018;10:1307–20.

    PubMed  PubMed Central  Google Scholar 

  29. Humans IWGotEoCRt. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. In: Drinking Coffee, Mate, and Very Hot Beverages. Lyon (FR): International Agency for Research on Cancer© International Agency for Research on Cancer, 2018. For more information contact publications@iarc.fr.; 2018.

  30. Choi Y, Song S, Song Y, Lee JE. Consumption of red and processed meat and esophageal cancer risk: meta-analysis. World J Gastroenterol. 2013;19(7):1020–9.

    PubMed  PubMed Central  Google Scholar 

  31. Fan Y, Yuan J-M, Wang R, Gao Y-T, Yu MC. Alcohol, tobacco, and diet in relation to esophageal cancer: the Shanghai Cohort Study. Nutr Cancer. 2008;60(3):354–63.

    PubMed  PubMed Central  Google Scholar 

  32. Blaydon DC, Etheridge SL, Risk JM, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet. 2012;90(2):340–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Ellis A, Risk JM, Maruthappu T, Kelsell DP. Tylosis with oesophageal cancer: diagnosis, management and molecular mechanisms. Orphanet J Rare Dis. 2015;10:126.

    PubMed  PubMed Central  Google Scholar 

  34. Ellis A, Field JK, Field EA, et al. Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family—a review of six generations. Eur J Cancer B Oral Oncol. 1994;30b(2):102–12.

    CAS  PubMed  Google Scholar 

  35. Cunniff C, Bassetti JA, Ellis NA. Bloom’s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol. 2017;8(1):4–23.

    CAS  PubMed  Google Scholar 

  36. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes — second edition. J Natl Cancer Inst Monogr. 2008;(38):1–93.

  37. Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018;18(3):168–85.

    CAS  PubMed  Google Scholar 

  38. Yang S-J, Yokoyama A, Yokoyama T, et al. Relationship between genetic polymorphisms of ALDH2 and ADH1B and esophageal cancer risk: a meta-analysis. World J Gastroenterol. 2010;16(33):4210–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Zhang G, Mai R, Huang B. ADH1B Arg47His polymorphism is associated with esophageal cancer risk in high-incidence Asian population: evidence from a meta-analysis. PloS One. 2010;5(10):e13679.

    PubMed  PubMed Central  Google Scholar 

  40. Mita Y, Yasuda Y, Sakai A, et al. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J Cancer Res Clin Oncol. 2010;136(2):249–59.

    CAS  PubMed  Google Scholar 

  41. Committee ASoP, Pasha SF, Acosta RD, et al. The role of endoscopy in the evaluation and management of dysphagia. Gastrointest Endosc. 2014;79(2):191–201.

    Google Scholar 

  42. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28. quiz 329.

    PubMed  Google Scholar 

  43. •di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018;154(2):421–36. Comprehensive review of endoscopic diagnosis, screening and management of esophageal carcinoma. A discussion of the merits of endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR). Also includes a descriptioN of non-endoscopic screening strategies.

    PubMed  Google Scholar 

  44. •Li S, Chung DC, Mullen JT. Screening high-risk populations for esophageal and gastric cancer. J Surg Oncol. 2019;120(5):831–46. A summary of current screening recommendations including appropriate populations and non-traditional techniques.

    PubMed  Google Scholar 

  45. Morita FH, Bernardo WM, Ide E, et al. Narrow band imaging versus lugol chromoendoscopy to diagnose squamous cell carcinoma of the esophagus: a systematic review and meta-analysis. BMC Cancer. 2017;17(1):54.

    PubMed  PubMed Central  Google Scholar 

  46. Yip HC, Chiu PW. Endoscopic diagnosis and management of early squamous cell carcinoma of esophagus. J Thorac Dis. 2017;9(Suppl 8):S689–96.

    PubMed  PubMed Central  Google Scholar 

  47. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.

  48. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119–30.

    PubMed  PubMed Central  Google Scholar 

  49. Luo LN, He LJ, Gao XY, et al. Endoscopic ultrasound for preoperative esophageal squamous cell carcinoma: a meta-analysis. PLoS One. 2016;11(7):e0158373.

    PubMed  PubMed Central  Google Scholar 

  50. Network NCC. Esophageal and Esophagogastric Junction Cancers (Version 1.20210. 2021. https://www.nccn.org/professionals/physician_gls/pdf/esophageal_blocks.pdf. Published 2021. Accessed March 7, 2021.

  51. Kutup A, Link BC, Schurr PG, et al. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy. 2007;39(8):715–9.

    CAS  PubMed  Google Scholar 

  52. Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, diagnosis, staging and multimodal therapy of esophageal and gastric tumors. Cancers (Basel). 2021;13(3).

  53. Convie L, Thompson RJ, Kennedy R, Clements WD, Carey PD, Kennedy JA. The current role of staging laparoscopy in oesophagogastric cancer. Ann R Coll Surg Engl. 2015;97(2):146–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Cardona K, Zhou Q, Gonen M, et al. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy. Ann Surg Oncol. 2013;20(2):548–54.

    PubMed  Google Scholar 

  55. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265(10):1287–9.

    CAS  PubMed  Google Scholar 

  56. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049–53.

    CAS  PubMed  Google Scholar 

  57. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38–44.

    PubMed  Google Scholar 

  58. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2–9.

    PubMed  Google Scholar 

  59. Francis DO, Weymuller EA Jr, Parvathaneni U, Merati AL, Yueh B. Dysphagia, stricture, and pneumonia in head and neck cancer patients: does treatment modality matter? Ann Otol Rhinol Laryngol. 2010;119(6):391–7.

    PubMed  Google Scholar 

  60. Melhado RE, Alderson D, Tucker O. The changing face of esophageal cancer. Cancers. 2010;2(3):1379–404.

    PubMed  PubMed Central  Google Scholar 

  61. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005;113(3):456–63.

    CAS  PubMed  Google Scholar 

  62. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–7.

    PubMed  Google Scholar 

  63. Yokoyama A, Kakiuchi N, Yoshizato T, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565(7739):312–7.

    CAS  PubMed  Google Scholar 

  64. •Li XC, Wang MY, Yang M, et al. A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann Oncol. 2018;29(4):938–44. A molecular link between alcohol consumption and significantly mutated genes driving oncogenesis in squamous cell cancer of the esophagus.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Cancer Genome Atlas Research N, Analysis Working Group: Asan U, Agency BCC, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75.

    Google Scholar 

  66. Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509(7498):91–5.

    CAS  PubMed  Google Scholar 

  67. McDowell LJ, Huang SH, Xu W, et al. Effect of intensity modulated radiation therapy with concurrent chemotherapy on survival for patients with cervical esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2017;98(1):186–95.

    PubMed  Google Scholar 

  68. Buckstein M, Liu J. Cervical esophageal cancers: challenges and opportunities. Curr Oncol Rep. 2019;21(5):46.

    PubMed  Google Scholar 

  69. Takebayashi K, Tsubosa Y, Matsuda S, et al. Comparison of curative surgery and definitive chemoradiotherapy as initial treatment for patients with cervical esophageal cancer. Dis Esophagus. 2017;30(2):1–5.

    PubMed  Google Scholar 

  70. Chen P, Zhao X, Zhou F, et al. Characterization of 500 Chinese patients with cervical esophageal cancer by clinicopathological and treatment outcomes. Cancer Biol Med. 2020;17(1):219–26.

    PubMed  Google Scholar 

  71. Cao CN, Luo JW, Gao L, et al. Primary radiotherapy compared with primary surgery in cervical esophageal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(10):918–26.

    PubMed  Google Scholar 

  72. Takebayashi K, Tsubosa Y, Kamijo T, et al. Comparison of salvage total pharyngolaryngectomy and cervical esophagectomy between hypopharyngeal cancer and cervical esophageal cancer. Ann Surg Oncol. 2017;24(3):778–84.

    PubMed  Google Scholar 

  73. Schieman C, Wigle DA, Deschamps C, et al. Salvage resections for recurrent or persistent cancer of the proximal esophagus after chemoradiotherapy. Ann Thorac Surg. 2013;95(2):459–63.

    PubMed  Google Scholar 

  74. Cao C, Luo J, Gao L, et al. Definitive radiotherapy for cervical esophageal cancer. Head Neck. 2015;37(2):151–5.

    PubMed  Google Scholar 

  75. Zhang P, Xi M, Zhao L, et al. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2015;116(2):257–61.

    PubMed  Google Scholar 

  76. Li HX, Liu J, Cheng Y, Liu MN, Fang WT, Lv CX. Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study. Dis Esophagus. 2018;31(5).

  77. Zenda S, Kojima T, Kato K, et al. Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Radiat Oncol Biol Phys. 2016;96(5):976–84.

    CAS  PubMed  Google Scholar 

  78. De B, Rhome R, Doucette J, Buckstein M. Dose escalation of definitive radiation is not associated with improved survival for cervical esophageal cancer: a National Cancer Data Base (NCDB) analysis. Dis Esophagus. 2017;30(4):1–10.

    CAS  PubMed  Google Scholar 

  79. •Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48. Phase III study of advanced esophageal cancer which progressed after initial therapy comparing pembrolizumab with chemotherapy. Pembrolizumab therapy prolonged overall survival in patients with high PD-L1.

    CAS  PubMed  Google Scholar 

  80. Lorenzo D, Barret M, Leblanc S, et al. Outcomes of endoscopic submucosal dissection for early oesophageal squamous cell neoplasia at a Western centre. United European Gastroenterol J. 2019;7(8):1084–92.

    PubMed  PubMed Central  Google Scholar 

  81. Othman MO, Lee JH, Wang K. Clinical practice update on the utility of endoscopic submucosal dissection in T1b esophageal cancer: expert review. Clin Gastroenterol Hepatol. 2019;17(11):2161–6.

    PubMed  Google Scholar 

  82. Tanaka T, Ueno M, Iizuka T, Hoteya S, Haruta S, Udagawa H. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma. Dis Esophagus. 2019;32(12).

  83. Borggreve AS, Kingma BF, Domrachev SA, et al. Surgical treatment of esophageal cancer in the era of multimodality management. Ann N Y Acad Sci. 2018;1434(1):192–209.

    PubMed  Google Scholar 

  84. Groth SS, Burt BM. Minimally invasive esophagectomy: Direction of the art. J Thorac Cardiovasc Surg. 2021.

  85. D’Amico TA. Mckeown esophagogastrectomy. J Thorac Dis. 2014;6 Suppl 3:S322-324.

    PubMed  Google Scholar 

  86. Blackmon SH, Correa AM, Skoracki R, et al. Supercharged pedicled jejunal interposition for esophageal replacement: a 10-year experience. Ann Thorac Surg. 2012;94(4):1104–11; discussion 1111-1103.

    PubMed  Google Scholar 

  87. ••van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. Landmark study of neoadjuvant chemoradiation with surgery versus surgery alone in a mixed population of adenocarcinoma and squamous carcinoma. Chemotherapy included carboplatin and paclitaxel with 41.4Gy of radiation. This study changed the standard of care for locally advanced esophageal cancer.

    PubMed  Google Scholar 

  88. •Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8. One of the rare randomized trials comparing neoadjuvant chemoradiation with surgery to chemoradiation alone in France. This trial also provided important information non-responders.

    CAS  PubMed  Google Scholar 

  89. •Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7. An early randomized trial of neoadjuvant chemoradiation versus chemoradiation alone. There was no significant difference but the surgical arm had a relatively high surgical mortality.

    PubMed  Google Scholar 

  90. Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev. 2017;8:CD010511.

    PubMed  Google Scholar 

  91. Ilson DH. Surgery after primary chemoradiotherapy in squamous cancer of the esophagus: is the photon mightier than the sword? J Clin Oncol. 2007;25(10):1155–6.

    CAS  PubMed  Google Scholar 

  92. ••Barbetta A, Hsu M, Tan KS, et al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2018;155(6):2710-2721 e2713. A retrospective cohort analysis of stage II and III squamous cell carcinomas comparing neoadjuvant chemoradiation and surgery to definitive chemoradiation. This patient cohort is the most common scenario when there is a question about resection. Neoadjuvant chemoradiation with surgery was associated with improved overall and disease-free survival as well as decreated local recurrence.

    PubMed  PubMed Central  Google Scholar 

  93. Kranzfelder M, Schuster T, Geinitz H, Friess H, Buchler P. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 2011;98(6):768–83.

    CAS  PubMed  Google Scholar 

  94. ••Yang H, Liu H, Chen Y, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–803. A randomized trial of neoadjuvant chemoradiation (NCRT) followed by surgery versus surgery alone for locally advanced squamous cell carcinoma. Patients received vinorelbine and cisplatin and 40.0 Gy of radiation. NCRT showed improved survival in this exclusive cohort of squamous cell carcinoma patients.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. •Pasquali S, Yim G, Vohra RS, et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis. Ann Surg. 2017;265(3):481–91. Meta-analysis of 33 randomized controlled trials of neoadjuvant and adjuvant therapies compared to surger alone. Neoadjuvant chemoradiation was found to be the most effective in improving survival.

    PubMed  Google Scholar 

  96. Montagnani F, Fornaro L, Frumento P, Vivaldi C, Falcone A, Fioretto L. Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: a comprehensive review and network meta-analysis. Crit Rev Oncol Hematol. 2017;114:24–32.

    PubMed  Google Scholar 

  97. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D, Committee EG. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.

    CAS  PubMed  Google Scholar 

  98. Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16(1):1–24.

    PubMed  Google Scholar 

  99. Piessen G, Messager M, Mirabel X, et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg. 2013;258(5):793–9; discussion 799-800.

    PubMed  Google Scholar 

  100. Castoro C, Scarpa M, Cagol M, et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary? J Gastrointest Surg. 2013;17(8):1375–81.

    PubMed  Google Scholar 

  101. Ellrichmann M, Sergeev P, Bethge J, et al. Prospective evaluation of malignant cell seeding after percutaneous endoscopic gastrostomy in patients with oropharyngeal/esophageal cancers. Endoscopy. 2013;45(7):526–31.

    CAS  PubMed  Google Scholar 

  102. van der Schaaf MK, Tilanus HW, van Lanschot JJ, et al. The influence of preoperative weight loss on the postoperative course after esophageal cancer resection. J Thorac Cardiovasc Surg. 2014;147(1):490–5.

    PubMed  Google Scholar 

  103. Leng XF, Daiko H, Han YT, Mao YS. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. Ann N Y Acad Sci. 2020;1482(1):213–24.

    PubMed  Google Scholar 

  104. Messager M, Mirabel X, Tresch E, et al. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. BMC Cancer. 2016;16:318.

    PubMed  PubMed Central  Google Scholar 

  105. von Dobeln GA, Klevebro F, Jacobsen AB, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis Esophagus. 2019;32(2).

  106. Nayan N, Bhattacharyya M, Jagtap VK, Kalita AK, Sunku R, Roy PS. Standard-dose versus high-dose radiotherapy with concurrent chemotherapy in esophageal cancer: a prospective randomized study. South Asian J Cancer. 2018;7(1):27–30.

    PubMed  PubMed Central  Google Scholar 

  107. Kumagai K, Mariosa D, Tsai JA, et al. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. Dis Esophagus. 2016;29(7):734–9.

    CAS  PubMed  Google Scholar 

  108. Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33(33):3866–73.

    CAS  PubMed  Google Scholar 

  109. Broderick RC, Lee AM, Blitzer RR, et al. It’s not always too late: a case for minimally invasive salvage esophagectomy. Surg Endosc. 2021;35(8):4700–11.

    PubMed  Google Scholar 

  110. Vincent J, Mariette C, Pezet D, et al. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: chemoradiation followed by surgery versus chemoradiation alone. Eur J Cancer. 2015;51(13):1683–93.

    PubMed  Google Scholar 

  111. ••Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203. Checkmate 577 a global randomized double blinded study of adjuvant checkpoint inhibitor in patients with residual disease after induction chemoradiation and surgery. Nivolumab was especially effective in patients with squamous cell carcinoma and those with high PD-L1 expression. This study led to a change in NCCN guidelines recommending adjuvant nivolumab for all patients with residual disease.

    CAS  PubMed  Google Scholar 

  112. Imai T, Tanaka Y, Sato Y, et al. The role of adjuvant chemotherapy for esophageal squamous cell carcinoma patients with pathological positive lymph nodes after neoadjuvant chemotherapy followed by esophagectomy: a single institute retrospective analysis. Indian J Surg Oncol. 2021.

  113. Mokdad AA, Yopp AC, Polanco PM, et al. Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis. JAMA Oncol. 2018;4(1):31–8.

    PubMed  Google Scholar 

  114. Semenkovich TR, Subramanian M, Yan Y, et al. Adjuvant therapy for node-positive esophageal cancer after induction and surgery: a multisite study. Ann Thorac Surg. 2019;108(3):828–36.

    PubMed  PubMed Central  Google Scholar 

  115. Yan W, Zhao P, Fu H, et al. Survival after induction chemotherapy and esophagectomy is not improved by adjuvant chemotherapy. Ann Thorac Surg. 2019;108(5):1505–13.

    PubMed  Google Scholar 

  116. Zhao Y, Dai Z, Min W, et al. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial. J Thorac Oncol. 2015;10(9):1349–56.

    CAS  PubMed  Google Scholar 

  117. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.

    CAS  PubMed  Google Scholar 

  118. Hirose T, Yamamoto S, Kato K. Emerging data on nivolumab for esophageal squamous cell carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15(8):845–54.

    CAS  PubMed  Google Scholar 

  119. van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15(4):235–49.

    PubMed  Google Scholar 

  120. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5(4):546–50.

    PubMed  Google Scholar 

  121. Kato K, Sun JM, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31:S1192–3.

    Google Scholar 

  122. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590–9.

    CAS  PubMed  Google Scholar 

  123. Xu J, Lu D, Zhang L, Li J, Sun G. Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer. Cancer Med. 2019;8(17):7253–64.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Department of Cardiovascular and Thoracic Surgery, 5323 Harry Hines Boulevard, MC 8879, Dallas, TX, 75390-8879, USA

    John K. Waters & Scott I. Reznik

Authors
  1. John K. Waters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott I. Reznik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott I. Reznik.

Ethics declarations

Conflict of Interest

John K. Waters declares that he has no conflict of interest. Scott I. Reznik is an investor/stockholder for OncoNano Medicine.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Gastrointestinal Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Waters, J.K., Reznik, S.I. Update on Management of Squamous Cell Esophageal Cancer. Curr Oncol Rep 24, 375–385 (2022). https://doi.org/10.1007/s11912-021-01153-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-021-01153-4

Keywords

Search

Navigation